Bonnie Elyssa Gould Rothberg MD, PhD, MPH
Assistant Professor of Medicine (Medical Oncology), of Epidemiology (Chronic Diseases) and of Pathology
Molecular cancer epidemiology; Cancer prognosis; Melanoma; Skin cancer; Lung cancer; Pancreatic Neuroendocrine Tumors (PNETs); Tuberous Sclerosis Complex; Next generation sequencing; Somatic tumor mutations; Germline genetic variation; Immunohistochemistry-based biomarkers; Biospecimens and biobanking; Lifestyle choices associated with cancer outcome
1. Molecular prognostic models for cutaneous melanoma metastases
2. Mechanisms of benign metastasis in kidney angiomyolipomas
3. Radiogenomics in lung cancer
4. Energy balance in Stage I non-small cell lung cancer prognosis
The prognosis for certain localized cancers, such as Stage II melanoma and Stage IA/IB non-small cell lung cancer is uncertain. Following curative-intent resection of the primary tumor, the long-term (5- or 10-year) overall survival for these patients can hover around 50%. At the same time, the morbidities associated with available adjuvant therapies precludes their use in the majority of these patients. Current prognostic models derived from conventional clinicopathologic parameters are insufficient to identify, at the time of diagnosis, the subset of patients at highest risk of recurrence for selective adjuvant therapy administration. The goal of my research program is to develop novel prognostic models for both early-stage non-small cell lung cancer and melanoma. Variables reflecting characteristics of the index tumor (somatic mutations, differential transcript profiling, differential protein expression), the patient's germline genetics as well as lifestyle behaviors are all simultaneously considered.